In Scientific American Mind, January 2004:
The use of antidepressants in children, always a warm subject, this year grew hot enough to burn, with revelations that both the drug industry and the FDA hid evidence that most SSRI (selective serotonin uptake inhibitor) antidepressants double suicide risk in depressed juveniles while helping children no more than placebos do. The story started as a trickle in spring and grew all summer, reaching a torrent at high-profile Congressional and FDA hearings in September , where parents told of good children moving from moderate depression to suicide within days of starting SSRIs. Some of these children died during the year during which the FDA delayed action. Congressional ubcommittee chair Joe Barton (R-Tex.) expressed the general reaction when he called the drug companies' withholding of data appalling and said the FDA's connivance suggested its initials stood for "foot-dragging and alibis." Even Dr. John Hayes, product team leader for Eli Lilly (whose Prozac was the one SSRI found both effective and safe) acknowledged the crisis atmosphere, noting with marked understatement that , "These hearings are evidence É there is a great deal of mistrust."
Click to read more ...